These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29441509)

  • 21. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
    Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
    PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation between IDH1 mutation and prognosis in supratentorial high-grade astrocytomas].
    Xie F; Tang JJ; Wang X; Liu YH; Mao Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 44(2):184-7, 192. PubMed ID: 23745251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
    Marker DF; Pearce TM
    Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas.
    Boustani MR; Khoshnood RJ; Nikpasand F; Taleshi Z; Ahmadi K; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Apr; 363():249-52. PubMed ID: 27000259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
    J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas.
    Carvalho PO; Uno M; Oba-Shinjo SM; Rosemberg S; Wakamatsu A; da Silva CC; Teixeira MJ; Marie SK
    Int J Biol Markers; 2014 Jun; 29(2):e120-8. PubMed ID: 24170555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
    Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade.
    Zhu C; Kros JM; van der Weiden M; Zheng P; Cheng C; Mustafa DA
    Acta Neuropathol Commun; 2017 Jan; 5(1):4. PubMed ID: 28073370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
    Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
    Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors.
    Abd El Atti RM; Abou Gabal HH; Osman WM; Saad AS
    Diagn Pathol; 2013 Jul; 8():126. PubMed ID: 23902708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
    Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
    Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High ATP2A2 expression correlates with better prognosis of diffuse astrocytic tumor patients.
    Li WQ; Zhong NZ; He J; Li YM; Hou LJ; Liu HM; Xia CY; Wang LZ; Lu YC
    Oncol Rep; 2017 May; 37(5):2865-2874. PubMed ID: 28339043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
    Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
    Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.